New drug IBI362 takes on semaglutide in fatty liver showdown
NCT ID NCT06884293
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a new weekly injection called IBI362 works better than the existing drug semaglutide for weight loss and reducing liver fat in overweight or obese Chinese adults with metabolic dysfunction-associated fatty liver disease (MAFLD). About 479 participants will receive either IBI362 or semaglutide for 48 weeks, followed by a 12-week safety check. The goal is to see which drug is more effective at helping people lose weight and lower fat in their liver.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE (MAFLD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Hospital
Beijing, Beijing Municipality, 100730, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new stomach and gut bypass surgery tackle obesity and diabetes?
- Can a Two-Drug combo tip the scales against obesity?
- Can Weight-Loss surgery change how medications work?
- Coffee grounds probiotic could reshape gut health and fight inflammation
- Can shedding pounds reboot the Heart's exercise engine?
- Can stomach surgery alter how painkillers work?